SCHEMBL1166892

SCHEMBL1166892

CC(F)(F)c1ccc(Cn2ccc(NC(=O)C=Cc3cccc(C(F)(F)F)c3)n2)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
HSP90AA1 P07900 1/20 0.48
PKM P14618 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 1/20 0.47
THRB P10828 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAOB P27338 2/20 0.45
CA12 O43570 3/20 0.43
CA9 Q16790 3/20 0.43
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
MAOA P21397 1/20 0.41
FLT3 P36888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1166954 1.00 MEN1 (0.48) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL1166890 1.00 MEN1 (0.48) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL1167191 0.90 CACNA1G (0.43) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL1167251 0.90 CACNA1G (0.43) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL1167193 0.90 CACNA1G (0.43) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL1166366 0.90 SMN1; SMN2 (0.43) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL1166365 0.90 SMN1; SMN2 (0.43) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL1166201 0.88 ALDH1A1 (0.43) MEN1KMT2AMAPTLMNAHTT
SCHEMBL1167397 0.88 ALDH1A1 (0.43) MEN1KMT2AMAPTLMNAHTT
SCHEMBL1166202 0.88 ALDH1A1 (0.43) MEN1KMT2AMAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP claimed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US claimed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US claimed
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 MEN1 2602/4885KMT2A 2299/4885MAPT 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.